Australia’s Therapeutic Goods Administration granted conditional approval on June 3, 2026, to Amtagvi (lifileucel) for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and, where applicable, a BRAF inhibitor with or without a MEK inhibitor. The decision makes lifileucel the first tumour-infiltrating lymphocyte (TIL) therapy and the first T cell immunotherapy of any kind to receive marketing authorisation in Australia.
Lifileucel is manufactured from a patient’s own tumour tissue. Surgeons excise a melanoma lesion and ship it to a central manufacturing facility, where TILs are isolated, expanded ex vivo over several weeks to generate billions of anti-tumour T cells, and then infused back into the patient following a lymphodepletion conditioning regimen. The process is logistically demanding and expensive, but it equips the immune system with a diverse, polyclonal army of cells that have already demonstrated natural reactivity to the patient’s own cancer antigens.
The TGA approval rests on data from the C-144-01 clinical trial, an open-label, single-arm, multicentre study that enrolled patients with advanced melanoma after failure of checkpoint inhibitor therapy. Across the evaluable population, lifileucel produced objective responses in approximately 31 percent of patients — a meaningful result in a setting where salvage options are sparse and median survival is typically measured in months.
The approval is geographically significant. Australia records roughly 17,000 new melanoma cases annually and has the highest per-capita melanoma incidence of any country in the world, driven by high ultraviolet radiation exposure and a historically sun-exposed population. Despite aggressive national screening campaigns, a substantial proportion of patients present at advanced stage or progress through first-line checkpoint inhibition, creating an unmet clinical need that lifileucel now partially addresses.
This is the third global marketing authorisation for Amtagvi, following approvals in the United States and the European Union. Iovance has indicated it will work with Australian hospital networks to establish the manufacturing and clinical infrastructure required for TIL therapy delivery, which requires specialist centres capable of managing the intensive lymphodepletion and post-infusion monitoring protocols.
The approval arrives as Australia’s oncology community increasingly participates in global cell and gene therapy development. Australia’s regulatory framework — including the TGA’s expedited pathways for innovative therapies and the country’s R&D Tax Incentive programme — has made it an attractive site for early-phase and pivotal trials in the CAR-T and TIL spaces. Clinical research organisations active in the ANZ region are well-positioned to support the site activation and patient identification work needed to make lifileucel commercially accessible to eligible Australians.
For patients who have exhausted anti-PD-1 therapy and face a disease that continues to advance, the arrival of a TIL-based option represents a genuine expansion of the treatment toolkit, even as the field waits for longer-term follow-up data on durability of response.
